DeepMed Research

MannKind Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 414

Market Cap: $1.4B

Website

Clinical Trials

A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus
Healthy Subjects

Interventions: Drug: Technosphere Insulin (TI) Inhalation Powder
Drug: Albuterol (Salbutamol)
Drug: Fluticasone

First Posted Date: 2008-05-07

Last Posted Date: 2012-06-13

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 13

Registration Number: NCT00674050

Locations: 🇬🇧
ICON Development Solutions, Manchester, United Kingdom, United Kingdom

A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics

Phase 1

Completed

Conditions: Asthma
Diabetes Mellitus

Interventions: Drug: Technosphere Insulin Inhalation Powder
Drug: Salbutamol (Albuterol)
Drug: Methacholine chloride

First Posted Date: 2008-05-07

Last Posted Date: 2012-06-13

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 30

Registration Number: NCT00673621

Locations: 🇬🇧
ICON Development Solutions, Manchester, United Kingdom
🇬🇧
Medicines Evaluation Unit (MEU), Manchester, England, United Kingdom

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Phase 2

Completed

Conditions: Diabetes Mellitus: Type 1

Interventions: Drug: RAA Population
Drug: Technosphere® Insulin Inhalation Powder
Drug: Technosphere Insulin® Inhalation Powder

First Posted Date: 2008-04-21

Last Posted Date: 2014-10-16

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 29

Registration Number: NCT00662857

Locations: 🇺🇸
Profil Institute for Clinical Research Inc., Chula Vista, California, United States
🇺🇸
Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: MKC253 Inhalation Powder
Drug: Technosphere Inhalation Powder
Drug: subcutaneous injection

First Posted Date: 2008-03-25

Last Posted Date: 2012-06-14

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 20

Registration Number: NCT00642538

Locations: 🇳🇱
University Medical Centre Groningen, Zuidlaren, Netherlands

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Phase 3

Terminated

Conditions: Type 1 Diabetes Mellitus
Asthma
Type 2 Diabetes Mellitus
Moderate Chronic Obstructive Pulmonary Disease

Interventions: Drug: Technosphere® Insulin
Drug: Usual Care

First Posted Date: 2008-03-25

Last Posted Date: 2017-04-14

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 34

Registration Number: NCT00642616

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Completed

Conditions: Diabetes Mellitus
Upper Respiratory Infection

Interventions: Drug: Technosphere Insulin

First Posted Date: 2008-03-25

Last Posted Date: 2014-12-03

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 20

Registration Number: NCT00642681

Locations: 🇷🇺
RAAMS Endocrinology and Diabetology Department, Moscow, RUS, Russian Federation
🇷🇺
Clinical Pharm Dept of Yaroslavl Clin Hospital, Yaroslavl, RUS, Russian Federation
🇷🇺
FSI Principal Military Clinical Hospital n.a. academician N.N. Burdenko of the Ministry of Defense, Moscow, Russian Federation

and more 21 locations

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Phase 1

Completed

Conditions: Mild Nephropathy
Moderate Nephropathy
Diabetes Mellitus

Interventions: Drug: Technosphere Inhalation Powder

First Posted Date: 2008-02-29

Last Posted Date: 2013-12-17

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 36

Registration Number: NCT00626249

Locations: 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Qualia Clinical Research, Omaha, Nebraska, United States
🇺🇸
Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States

A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Technosphere Insulin

First Posted Date: 2007-12-11

Last Posted Date: 2014-10-16

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 30

Registration Number: NCT00570687

Locations: 🇩🇪
Profil Institute for Metabolic Research, Neuss, GER, Germany

Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Type 2

First Posted Date: 2007-10-05

Last Posted Date: 2009-10-14

Lead Sponsor: Mannkind Corporation

Registration Number: NCT00539890

Locations: 🇷🇺
Russian State Medical University City Hospital # 4, Moscow, RUS, Russian Federation
🇷🇺
Ural State Medical Academy of Post-Graduate Education Municipal Clinical Hospital # 3, Chelyabinsk, RUS, Russian Federation
🇷🇺
Moscow Medical Academy, Moscow, RUS, Russian Federation

and more 29 locations

A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

First Posted Date: 2007-10-04

Last Posted Date: 2009-10-14

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 110

Registration Number: NCT00539396

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy